Foundations Investment Advisors LLC Sells 1,331 Shares of IQVIA Holdings Inc. $IQV

Foundations Investment Advisors LLC lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 34.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,506 shares of the medical research company’s stock after selling 1,331 shares during the period. Foundations Investment Advisors LLC’s holdings in IQVIA were worth $395,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. Everpar Advisors LLC grew its stake in shares of IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after buying an additional 62 shares during the last quarter. Private Trust Co. NA grew its position in IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the last quarter. Independent Advisor Alliance increased its stake in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after purchasing an additional 72 shares during the period. Nemes Rush Group LLC lifted its position in IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its stake in shares of IQVIA by 10.3% during the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after purchasing an additional 90 shares during the period. 89.62% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV opened at $217.50 on Thursday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $228.12. The company has a market cap of $37.04 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 2.44 and a beta of 1.34. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $204.51 and a two-hundred day simple moving average of $180.05.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the firm earned $2.84 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. UBS Group upped their price target on shares of IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. BMO Capital Markets started coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price on the stock. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and upped their price target for the company from $206.00 to $215.00 in a research report on Monday, November 3rd. Finally, JPMorgan Chase & Co. boosted their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $240.61.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.